Cure My Disease

Don't miss your cure!

 Log in / Sign up

Korean CML patients monitored on new drug scemblix

NCT ID NCT05943522

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 600 Korean adults with chronic myeloid leukemia who are taking Scemblix (asciminib) to see how safe and effective it is in everyday medical practice. Researchers will track side effects and how well the drug controls the disease at 12 and 24 weeks. The goal is to confirm real-world benefits and risks for patients already receiving this medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOID LEUKEMIA

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Wŏnju, Gangwon-do, 26426, South Korea

  • Novartis Investigative Site

    RECRUITING

    Anyang-si, Gyeonggi-do, 14068, South Korea

  • Novartis Investigative Site

    RECRUITING

    Bucheon-si, Gyeonggi-do, 14584, South Korea

  • Novartis Investigative Site

    RECRUITING

    Uijeongbu-si, Gyeonggi-do, 11759, South Korea

  • Novartis Investigative Site

    RECRUITING

    Gyeonggi-do, Korea, 10408, South Korea

  • Novartis Investigative Site

    RECRUITING

    Incheon, Korea, 405 760, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Korea, 02841, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 03080, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 06351, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Yangcheon gu, 07985, South Korea

  • Novartis Investigative Site

    RECRUITING

    Suwon, Yeongtong Gu, 16499, South Korea

  • Novartis Investigative Site

    RECRUITING

    Jeollanam, 519763, South Korea

  • Novartis Investigative Site

    RECRUITING

    Pusan, 614 735, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 06591, South Korea

  • Novartis Investigative Site

    RECRUITING

    Taegu, 41944, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.